You just read:

Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

News provided by

Infinity Pharmaceuticals, Inc.

Mar 14, 2019, 07:02 ET